Does every patient with enigmatic lung disease deserve a lung biopsy?
We recommend that the decision for lung biopsy be individualized based on respiratory status.
Using the largest DBS-based phenotyping study to date, we have demonstrated that CYP1A2 phenotyping in capillary DBS is a valid and convenient alternative for the classical plasma-based approach. Additionally, we have provided an objective basis as to why DBS are an ideal tool for CYP1A2 phenotyping.